Noxopharm Limited Performance
| NOXOFDelisted Stock | USD 0.04 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Noxopharm are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Noxopharm Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Noxopharm is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
Noxopharm |
Noxopharm Relative Risk vs. Return Landscape
If you would invest 4.50 in Noxopharm Limited on October 2, 2025 and sell it today you would earn a total of 0.00 from holding Noxopharm Limited or generate 0.0% return on investment over 90 days. Noxopharm Limited is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Noxopharm, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Noxopharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Noxopharm's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Noxopharm Limited, and traders can use it to determine the average amount a Noxopharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| NOXOF |
Based on monthly moving average Noxopharm is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Noxopharm by adding Noxopharm to a well-diversified portfolio.
Noxopharm Fundamentals Growth
Noxopharm Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Noxopharm, and Noxopharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Noxopharm Pink Sheet performance.
| Return On Equity | -0.58 | |||
| Return On Asset | -0.16 | |||
| Operating Margin | (1.80) % | |||
| Current Valuation | 22.3 M | |||
| Shares Outstanding | 292.24 M | |||
| Price To Book | 2.36 X | |||
| Price To Sales | 7.11 X | |||
| Revenue | 5.43 M | |||
| EBITDA | (18.33 M) | |||
| Cash And Equivalents | 14.01 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 160.62 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (13.73 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 26.59 M | |||
About Noxopharm Performance
By analyzing Noxopharm's fundamental ratios, stakeholders can gain valuable insights into Noxopharm's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Noxopharm has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Noxopharm has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. The company was incorporated in 2015 and is based in Chatswood, Australia. Noxopharm operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Noxopharm Limited performance evaluation
Checking the ongoing alerts about Noxopharm for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Noxopharm Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Noxopharm Limited is not yet fully synchronised with the market data | |
| Noxopharm Limited has some characteristics of a very speculative penny stock | |
| Noxopharm Limited has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 5.43 M. Net Loss for the year was (18.67 M) with loss before overhead, payroll, taxes, and interest of (2.35 M). | |
| Noxopharm Limited has accumulated about 14.01 M in cash with (13.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 34.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Noxopharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Noxopharm's stock is overvalued or undervalued compared to its peers.
- Examining Noxopharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Noxopharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Noxopharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Noxopharm's pink sheet. These opinions can provide insight into Noxopharm's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Noxopharm Pink Sheet
If you are still planning to invest in Noxopharm Limited check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Noxopharm's history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |